SlowBull
The Business Brief WEDNESDAY, 2 SEPTEMBER 2026
← All stories
Markets

Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity

1 source ·1 article ·7h ago

Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the broader health care sector.

Covered by 1 outlet

Marketbeat 1

All coverage · 1 article

MarketBeat ·7h ago

Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity

Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the broader health care sector.